Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation

Drugs under Experimental and Clinical Research

Volumn 30, Issue 4, 2004, Pages 169-175

  Yamagishi, S ^a   Takeuchi, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; NIFEDIPINE; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NIFEDIPINE; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN; UMBILICAL VEINS;

EID: 8444249207     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharm. Res., 23, 129, 2003.
2. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med, 318, 1315, 1988.
3. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem., 266, 11654, 1991.
4. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease. Role of advanced glycation end product receptors. Diabetes Suppl., 3, S65, 1996.
5. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun., 213, 68, 1995.
6. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun., 290, 973, 2002.
7. Yamagishi S., Inagaki Y., Amano S., et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
8. Yamagishi S., Okamoto T., Amano S., et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med., 8, 178, 2002.
9. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy Biochem. Biophys. Res. Commun., 213, 681, 1995.
10. 2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol. Med., 8, 547, 2002.
11. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 41, 1435, 1998.
12. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
13. Yamagishi S., Yonekura H., Yamamoto Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
14. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
15. Okamoto T., Yamagishi S., Inagaki Y., et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem. Biophys. Res. Commun., 297, 419, 2002.
16. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309, 2002.
17. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int., 63, 464, 2003.
18. Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am. J. Pathol., 150, 523, 1997.
19. Bierhaus A., Hofmann M. A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res., 37, 586, 1998
20. Schmidt A.M., Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr. Atheroscler Rep., 2, 430, 2002.
21. Taddei S., Virdis A., Ghiadoni L., Sudanom I., Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr. Hypertens. Rep., 2, 64, 2000.
22. Taddei S., Virdis A., Ghiadoni L., et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens., 19, 1379, 2001.
23. Zanchetti A., Bond M.G. Hennig M., et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 106, 2422, 2002.
24. Nayler W.G. Review of preclinical data of calcium channel blockers and atherosclerosis. J. Cardiovasc. Pharmacol., 33(Suppl. 2), S7, 1999.
25. Mark I.T., Weglicki W.B. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol., 234, 620, 1994.
26. Yamagishi S., Inagaki Y., Abe R., Kikuchi S., Sasaki N., Takeuchi M. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-α. Drugs Exptl. Clin. Res., 24, 141, 2003.
27. Yamagishi S., Inagaki Y., Kikuchi S. Nifedipine inhibits tumor necrosis factor-α-induced monocyte chemoattractant protein-1 over-expression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exptl. Clin. Res., 24, 147, 2003.
28. Yamagishi S., Edelstein D., Du X.L., Kaneda Y., Guzmán M., Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem., 276, 25096, 2001.
29. Yamagishi S., Inagaki Y., Nakamura K., Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-α-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J. Cardiovasc. Pharmacol., 43, 724, 2004.
30. Yamagishi S., Amano S., Inagaki Y., et al. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs. Exp. Clin. Res., 24, 75, 2003.
31. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 275, 25781, 2000.
32. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 280, 685, 2001.
33. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Cir. Res., 86, 494 2000.
34. Kunsch, C., Medford P.M. Oxidative stress as a regulator of gene expression in the vasculature. Cir. Res., 85, 753, 1999.
35. Vehaar M.C., Honing M.L., van Dam T., et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res., 42, 752, 1999.
36. Herbette L.G., Vant Erve Y.M., Rhodes D.G. Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: Lipid bilayer partitioning could occur before drug binding to receptors. J. Mol. Cell. Cardiol., 21, 187, 1989.
37. Schmidt A.M., Stern D.M. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab., 11, 368, 2000.
38. Takeuchi M., Kikuchi S., Sasaki N., et al. Involvement of advanced glycation end products (AGEs) in Alzheimer's disease. Curr. Alzheimer Res., 1, 39, 2004.
39. Abe R., Shimizu T., Sugawara H., et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol., 122, 461, 2004.